Bipolar

#Bipolar #Johnson & Johnson #Neuroscience #Phase III trial #Psychiatry

Phase III study supports lumateperone use in bipolar mania

Johnson & Johnson has announced positive topline results from a Phase III study evaluating Caplyta (lumateperone) for the treatment of manic episodes with or without mixed features in adults with bipolar I disorder.   The study met its primary endpoint, with Caplyta demonstrating a statistically significant and rapid… Read More

#News

Neuroscience Parkinson's disease
#Autobahn Therapeutics #Bipolar #Neuroscience #Phase II trial #Psychiatry

Bipolar treatment leads to rapid antidepressant effects

A treatment for patients with bipolar I or bipolar II depression has demonstrated durable antidepressant effects, results show. Elunetirom, developed by Autobahn Therapeutics, is a novel, oral, once daily, brain-penetrant CNS thyroid hormone receptor agonist. In the Phase II AMPLIFY-BD trial, elunetirom was evaluated as an adjunctive… Read More

#News

Female medical researcher
#BioXcel Therapeutics #Bipolar #FDA #Schizophrenia

sNDA application submitted for agitation drug 

Biopharmaceutical company BioXcel Therapeutics has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for agitation treatment Igalmi.  Igalmi (dexmedetomidine) is a prescription medicine used for the acute treatment of agitation associated with schizophrenia and bipolar disorder I and II in adults.   In April 2022, Igalmi was… Read More

#News #Regulatory

#Artificial intelligence (AI) #Bipolar #CRISPR #Events #GLP-1 #Neuroscience #Society for Neuroscience #Stem cells

New DDW Highlights episode: 15 October 2024

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Recently, the Society for Neuroscience’s annual meeting took place, so… Read More

#News

#Artificial intelligence (AI) #Bipolar #CRISPR #Events #GLP-1 #Neuroscience #Society for Neuroscience #Stem cells

This week in drug discovery (7-11 Oct) 

News round-up for 7-11 October by DDW Senior Digital Content Editor Diana Spencer. The Society for Neuroscience annual meeting took place this week, so the headlines have been dominated by the latest discoveries related to the brain and the central nervous system, including significant findings related to GLP-1… Read More

#News

Neurons
#Bipolar #Neuroscience #Psychiatry #Society for Neuroscience #Walsh Research Institute

Breakthroughs in bipolar disorder announced at Neuroscience 2024

A Walsh Research Institute scientist presented an advanced theory of bipolar disorder at the annual meeting of the Society for Neuroscience, Neuroscience 2024. After a multi-year investigation of recent neuroscience advances, Dr William Walsh believes he has resolved many unknowns that have puzzled researchers for a… Read More

#News #Trending News

#Bipolar #Collaboration #Drug development #Pharmaceuticals

Partnership meets an unmet need for bipolar disorder patients 

Lo.Li. Pharma International has announced a new strategic partnering plan for its new product, Deplesin, which meets an unmet need for bipolar disorder (BD) patients. The discussions are underway with the aim of increasing accessibility to this novel adjunctive agent in the treatment of BD patients, who often experience a number… Read More

#News